Related Experiment Video
Updated: May 23, 2026
13:58
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Comprehensive analysis of unique cases with extraordinary control over HIV replication
Daniel Mendoza1, Sarah A Johnson, Bennett A Peterson
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
Blood
|April 12, 2012
Summary
Certain individuals control HIV without medication, exhibiting exceptionally low viral loads and weaker immune responses than typical elite controllers. This discovery offers new insights into HIV suppression mechanisms.
Area of Science:
- Immunology
- Virology
- Genetics
Background:
- True long-term nonprogressors (LTNPs) and elite controllers (ECs) naturally control Human Immunodeficiency Virus (HIV) replication without antiretroviral therapy.
- Typical LTNPs/ECs demonstrate robust immune responses, undetectable viral loads, and specific HLA alleles.
Observation:
- This study identifies four unique individuals with extraordinarily low HIV burdens and comparatively weaker immune responses than typical LTNPs/ECs.
- These individuals presented with weakly reactive HIV-1 Western blots, undetectable plasma viremia, and minimal HIV DNA levels.
Findings:
- The four unique cases exhibited distinct characteristics, including undetectable plasma viremia via single-copy assay and difficulty in isolating replication-competent HIV.
- While possessing protective HLA alleles, their CD8(+) T-cell responses were disproportionately high for the low antigen levels but lower than typical LTNPs/ECs.
Implications:
- These findings suggest a higher level of immune-mediated suppression over HIV replication than previously observed in LTNPs/ECs.
- Understanding these unique cases can enhance knowledge of HIV suppression mechanisms, potentially informing the development of novel HIV vaccines and immunotherapies.
